Document is current

Any future updates will be listed below

Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma

Crossref DOI link: https://doi.org/10.1186/s40164-017-0089-y

Published Online: 2017-11-06

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark